Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

Prior treatment

• Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included.

Other illness

• Patients treatment for restenosis or stent thrombosis.
• Patients with allergy to any of the components of the stent to be used.

Other

• Patients do not have to meet any exclusion criteria
• Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s).
• Patients presentation in cardiogenic shock or after cardiorespiratory arrest.
• Patients with impossibility for follow-up.
• Patients with life expectancy less than 1 year.

• Patients must meet all inclusion criteria:
• Patients with Signed informed consent and
• Patients with \>=18 years old and
• Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and
• Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used